Clinical Trials Browser

Muscle Invasive Bladder Cancer (MIBC) × disitamab vedotin × 90 days × Clear all

NCT07474064 2026-03-17

Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC

Phase 2 Not yet recruiting

Muscle Invasive Bladder Cancer (MIBC)